Drug facts
Semaglutide and breastfeeding
Quick answer
For the injection the label reports no data — on semaglutide in human milk, on the breastfed infant, or on milk production — and asks for the benefits of breastfeeding to be weighed against the mother’s clinical need. For the tablet it goes further and says breastfeeding is not recommended.
The injection1
Section 8.2 states plainly that there are no data on the presence of subcutaneously administered semaglutide or its metabolites in human milk, no data on effects on the breastfed infant, and none on milk production. What it asks for instead is a judgment: the developmental and health benefits of breastfeeding, weighed against the mother’s clinical need and any potential adverse effects.
That is the whole of it. A page that turned this into a recommendation either way would be supplying a conclusion the label declines to reach.
The tablet is different, and for a specific reason1
The oral formulation carries a stronger instruction — breastfeeding is not recommended — and the reason is not semaglutide. In a clinical lactation study, semaglutide itself was below the limit of quantification in human milk. What is present is SNAC, the absorption enhancer the tablet needs, and the enzymes that clear it may be less active in infants.
The label notes that alternative formulations without SNAC exist and can be used during lactation — which is to say the injection and the tablet are not interchangeable on this question, and the answer depends on which one is in front of you. A compounded vial is not a tablet, but nor has it been studied here at all.
What this page is not
This reports what the label states and, where it states nothing, says so. It is not advice — that is a conversation with the prescriber and with whoever is caring for the infant.
Sources
- FDA prescribing information for WEGOVY (semaglutide), section 8.2 Lactation, revision 6/2026 DailyMed